Signal Transduction and Targeted Therapy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2020-11-09 12034818m05(暂无昵称)

请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？

187 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2020-03-07 Smile S

您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表::
去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表:
去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下：
Waiting for Revision 3rd Jun 18 23:16:33
Decision Sent to Author 3rd Jun 18 23:16:33
Decision Made 3rd Jun 18 23:15:09
Manuscript Under Consideration 3rd Jun 18 23:14:28
Manuscript Under Consideration 14th May 18 03:25:03
Editor Assigned 14th May 18 02:09:17
Manuscript Received 14th May 18 02:09:16

sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16

174 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2021-03-05 AtoZ

审稿速度:3.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了...

255 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2021-09-29 ms6860193281304271

刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！

153 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2022-04-24 珍珍小坏

投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗

118 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2022-09-24 ms5000000203748297

请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭

84 0

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2022-09-03 ms4000000217931705

据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。

62 0

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2022-06-29 小小医者

38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了

95 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2020-06-21 尊严

能发Cell Death and Differentiation水平的文章投这个杂志合适不？

208 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=898092, encodeId=e54f89809250, content=请问下送审一定是会给通讯作者发邮件吗？有没有人送审了却没有收到送审邮件呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4e9e2162248, createdName=12034818m05(暂无昵称), createdTime=Mon Nov 09 22:45:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586084, encodeId=b2cf586084f0, content=您好，请问小修的decision是给了您多长的revise期限？是让你回答一些问题还是补实验呢？谢谢您看到sibs很亲切sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16sibs2009 2019-10-30 10:28:00 发表: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, beContent=sibs2009 2019-10-30 发表:: 去年在 STTT上发了一篇，投稿并小修的过程概况（以供参考）如下： Waiting for Revision 3rd Jun 18 23:16:33 Decision Sent to Author 3rd Jun 18 23:16:33 Decision Made 3rd Jun 18 23:15:09 Manuscript Under Consideration 3rd Jun 18 23:14:28 Manuscript Under Consideration 14th May 18 03:25:03 Editor Assigned 14th May 18 02:09:17 Manuscript Received 14th May 18 02:09:16, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM6v1585QCQbpmjXDyicYiacKibHqiaStxdoDCndvic4fIgOAJJp87iaNd3An40vzYrYc4kF01aa2qm1zMiag/132, createdBy=97d65283235, createdName=Smile S, createdTime=Sat Mar 07 00:00:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945665, encodeId=8ff294566573, content=审稿速度:3.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：去年投的文章，第一轮2个多月，3个审稿人给了几十条意见，比较中性，其中有一个比较看好，编辑给了大修；因为意见较多，我们重构了文章体系，补了近半年的实验，文章思路和质量已有质的飞跃，修回意见高洋洋洒洒十几页，投回去满心以为会直接过关了，但编辑又送审了，又来了俩审稿人，这次更加专业，提的问题直中要害，动物、临床和体外的分子实验都做了新的要求，感觉已跟子刊无异，甚至要求还要苛刻。现还在艰苦二修中，最近看到有好多人被要求转成Letter，所以也不敢怠慢。从投稿至此已经一年，希望努力最终能有收获，别再来一轮修了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0f55465788, createdName=AtoZ, createdTime=Fri Mar 05 10:39:02 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055985, encodeId=17db10559856a, content=刚接收一篇article。从投稿开始，历时4个月，共两轮修改。审稿人意见非常专业，编辑部老师也非常Nice。祝杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211014/4d07a2ac47344759befa282ab96f4fe4/eec488312d2746149070b3a4ec67872b.jpg, createdBy=03641833180, createdName=ms6860193281304271, createdTime=Wed Sep 29 10:32:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213983, encodeId=2be21213983ff, content=投的一篇综述，现在一直是manuscript under consideration，请问是送审了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/icyLhIGqru6hs9Qo1Mib4jmS4CiatwFItgPdXqZ5q6BBLibBsthxwP7Vd9z2VroiaasvHYYe9zV0ehje7icyjTcwHLaRrNvPyRia9ib9/0, createdBy=8e622061245, createdName=珍珍小坏, createdTime=Sun Apr 24 22:31:27 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090080, encodeId=76222090080e1, content=请问这个怎么同时添加两个通讯作者啊，系统默认是一个通讯作者😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75186460616, createdName=ms5000000203748297, createdTime=Sat Sep 24 10:29:12 CST 2022, time=2022-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242951, encodeId=9dea1242951d1, content=据说今年的文章名额已经被预定完了。研究性文章几乎不可能中，letter或者好的综述还是有希望的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Sat Sep 03 13:11:43 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229454, encodeId=b4511229454db, content=38分，通货膨胀的结果而已。分数已没有实际价值，关键看期刊以及文章的影响力了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Wed Jun 29 14:00:18 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799338, encodeId=c68be9933878, content=能发Cell Death and Differentiation水平的文章投这个杂志合适不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Sun Jun 21 22:44:32 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229144, encodeId=203d122914400, content=38分！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Tue Jun 28 13:42:51 CST 2022, time=2022-06-28, status=1, ipAttribution=)]

2022-06-28 wy-liang

38分！

79 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务